CN106434980A - Kit for detecting esophagus cancer susceptivity and SNP (single nucleotide polymorphism) marker of kit - Google Patents

Kit for detecting esophagus cancer susceptivity and SNP (single nucleotide polymorphism) marker of kit Download PDF

Info

Publication number
CN106434980A
CN106434980A CN201611049684.XA CN201611049684A CN106434980A CN 106434980 A CN106434980 A CN 106434980A CN 201611049684 A CN201611049684 A CN 201611049684A CN 106434980 A CN106434980 A CN 106434980A
Authority
CN
China
Prior art keywords
seq
sequence
pcr amplification
base extension
single base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201611049684.XA
Other languages
Chinese (zh)
Inventor
张核子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Nuclear Gene Technology Co Ltd
Original Assignee
Shenzhen Nuclear Gene Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Nuclear Gene Technology Co Ltd filed Critical Shenzhen Nuclear Gene Technology Co Ltd
Priority to CN201611049684.XA priority Critical patent/CN106434980A/en
Publication of CN106434980A publication Critical patent/CN106434980A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses an SNP (single nucleotide polymorphism) marker for detecting esophagus cancer susceptivity. The SNP marker comprises 24 SNP loci. The invention further discloses a PCR (polymerase chain reaction) amplification primer, a single-basic-group extension primer and a kit of the SNP marker. An important basis is provided for illness risk evaluation and diagnosis reference of esophagus cancer.

Description

A kind of kit for detecting esophageal cancer susceptibility and its SNP mark
Technical field
The invention belongs to Genetic Detection field, particularly to a kind of kit for detecting esophageal cancer susceptibility and its SNP mark.
Background technology
The cancer of the esophagus is the malignant tumour that Esophageal Mucosa epithelium and oesophagus galandular epithelium occur.Or inside and outside substantial amounts of association study table Bright, the morbidity of the cancer of the esophagus is relevant with inherent cause.
Using SNP (Single Nucleotide Polymorphsm, SNP) as genomic marker Association analysis method is one of inheritance susceptible gene tester of disease the most frequently used at present.SNP refers in genomic level The DNA sequence polymorphism being caused by single nucleotide variations, the occurrence frequency in crowd is more than 1%, and it is that the mankind are heritable Modal one kind in variation.By force it is easy to detect, the SNP positioned at gene internal can directly influence albumen to SNP genetic stability The structure of matter or expression, and then have influence on tissue, organ or even physiological function.
To common disease, related multiple genetic markers carry out early detection and system evaluation will be helpful to the early stage to disease Prevention, diagnosis and treatment.At present, research has been found that the related science of heredity mark of a large amount of and various common diseases, however, due to Lack and have enough sensitivity and multiple disease correlated identities can be carried out with extensively (high flux detection site, high flux detection Sample) examination and inspection method so that these common diseases science of heredity mark cannot extensively apply.Additionally, it is common at present Disease genetic mark shortage system, effectively integration, constrain sending out of common disease early prevention, diagnosis and treatment aspect significantly Exhibition.Existing detection only has the genetic marker detection of single kind of disease or a class disease, and detection range is limited, and some common diseases The method that there is no early detection.
At present, the detection of some traditional medicine means, such as histocyte has its intrinsic defect, position of drawing materials is improper, Histocyte sample material is not enough or thinks to lack experience etc. and all will lead to carcinoma of endometrium mistaken diagnosis.Other technologies such as iconography Although being widely used in inspection and the diagnosis of carcinoma of endometrium, its disease carcinoma of endometrium degree qualitative on still deposit In significant limitation.
In sum, research and development a kind of for by multiple susceptibility locis detect esophageal cancer susceptibility kit to the cancer of the esophagus The prediction of onset risk, prevention, diagnosis are provided according to significant.
Content of the invention
In view of the defect that above-mentioned prior art exists, the purpose of the present invention is to propose to one kind is used for detecting esophageal cancer susceptibility SNP mark, the pcr amplification primer thing of SNP mark and Single base extension primer and its kit, 24 SNP of the present invention Site is assessed, is diagnosed with reference to offer important evidence for the risk of the cancer of the esophagus.
The purpose of the present invention will be achieved by the following technical programs:
A kind of SNP mark for detecting esophageal cancer susceptibility, described SNP mark includes 24 SNP site, described 24 SNP site are rs10204525, rs1033667, rs1042026, rs1042522, rs10484761, rs11066015, rs11066280、rs1346044、rs1642764、rs17761864、rs1805034、rs1883965、rs2074356、 rs2239612、rs2274223、rs238406、rs2847281、rs35597309、rs4785204、rs4822983、 Rs63749993, rs671, rs7206735 and rs7447927.
The pcr amplification primer thing of above-mentioned SNP mark and Single base extension primer,
The sequence of the pcr amplification primer thing of described detection rs10204525 is respectively SEQ ID NO:1 and SEQ ID NO:2, And the sequence of Single base extension primer is SEQ ID NO:3;
The sequence of the pcr amplification primer thing of described detection rs1033667 is respectively SEQ ID NO:4 and SEQ ID NO:5, with And the sequence of Single base extension primer is SEQ ID NO:6;
The sequence of the pcr amplification primer thing of described detection rs1042026 is respectively SEQ ID NO:7 and SEQ ID NO:8, with And the sequence of Single base extension primer is SEQ ID NO:9;
The sequence of the pcr amplification primer thing of described detection rs1042522 is respectively SEQ ID NO:10 and SEQ ID NO:11, And the sequence of Single base extension primer is SEQ ID NO:12;
The sequence of the pcr amplification primer thing of described detection rs10484761 is respectively SEQ ID NO:13 and SEQ ID NO: 14, and the sequence of Single base extension primer be SEQ ID NO:15;
The sequence of the pcr amplification primer thing of described detection rs11066015 is respectively SEQ ID NO:16 and SEQ ID NO: 17, and the sequence of Single base extension primer be SEQ ID NO:18;
The sequence of the pcr amplification primer thing of described detection rs11066280 is respectively SEQ ID NO:19 and SEQ ID NO: 20, and the sequence of Single base extension primer be SEQ ID NO:21;
The sequence of the pcr amplification primer thing of described detection rs1346044 is respectively SEQ ID NO:22 and SEQ ID NO:23, And the sequence of Single base extension primer is SEQ ID NO:24;
The sequence of the pcr amplification primer thing of described detection rs1642764 is respectively SEQ ID NO:25 and SEQ ID NO:26, And the sequence of Single base extension primer is SEQ ID NO:27;
The sequence of the pcr amplification primer thing of described detection rs17761864 is respectively SEQ ID NO:28 and SEQ ID NO: 29, and the sequence of Single base extension primer be SEQ ID NO:30;
The sequence of the pcr amplification primer thing of described detection rs1805034 is respectively SEQ ID NO:31 and SEQ ID NO:32, And the sequence of Single base extension primer is SEQ ID NO:33;
The sequence of the pcr amplification primer thing of described detection rs1883965 is respectively SEQ ID NO:34 and SEQ ID NO:35, And the sequence of Single base extension primer is SEQ ID NO:36;
The sequence of the pcr amplification primer thing of described detection rs2074356 is respectively SEQ ID NO:37 and SEQ ID NO:38, And the sequence of Single base extension primer is SEQ ID NO:39;
The sequence of the pcr amplification primer thing of described detection rs2239612 is respectively SEQ ID NO:40 and SEQ ID NO:41, And the sequence of Single base extension primer is SEQ ID NO:42;
The sequence of the pcr amplification primer thing of described detection rs2274223 is respectively SEQ ID NO:43 and SEQ ID NO:44, And the sequence of Single base extension primer is SEQ ID NO:45;
The sequence of the pcr amplification primer thing of described detection rs238406 is respectively SEQ ID NO:46 and SEQ ID NO:47, And the sequence of Single base extension primer is SEQ ID NO:48;
The sequence of the pcr amplification primer thing of described detection rs2847281 is respectively SEQ ID NO:49 and SEQ ID NO:50, And the sequence of Single base extension primer is SEQ ID NO:51;
The sequence of the pcr amplification primer thing of described detection rs35597309 is respectively SEQ ID NO:52 and SEQ ID NO: 53, and the sequence of Single base extension primer be SEQ ID NO:54;
The sequence of the pcr amplification primer thing of described detection rs4785204 is respectively SEQ ID NO:55 and SEQ ID NO:56, And the sequence of Single base extension primer is SEQ ID NO:57;
The sequence of the pcr amplification primer thing of described detection rs4822983 is respectively SEQ ID NO:58 and SEQ ID NO:59, And the sequence of Single base extension primer is SEQ ID NO:60;
The sequence of the pcr amplification primer thing of described detection rs63749993 is respectively SEQ ID NO:61 and SEQ ID NO: 62, and the sequence of Single base extension primer be SEQ ID NO:63;
The sequence of the pcr amplification primer thing of described detection rs671 is respectively SEQ ID NO:64 and SEQ ID NO:65, and The sequence of Single base extension primer is SEQ ID NO:66;
The sequence of the pcr amplification primer thing of described detection rs7206735 is respectively SEQ ID NO:67 and SEQ ID NO:68, And the sequence of Single base extension primer is SEQ ID NO:69;
The sequence of the pcr amplification primer thing of described detection rs7447927 is respectively SEQ ID NO:70 and SEQ ID NO:71, And the sequence of Single base extension primer is SEQ ID NO:72.
A kind of kit for detecting esophageal cancer susceptibility, described kit includes SNP mark described in claim 2 Pcr amplification primer thing and Single base extension primer, for detect in peripheral blood DNA 24 SNP site be rs10204525, rs1033667、rs1042026、rs1042522、rs10484761、rs11066015、rs11066280、rs1346044、 rs1642764、rs17761864、rs1805034、rs1883965、rs2074356、rs2239612、rs2274223、 rs238406、rs2847281、rs35597309、rs4785204、rs4822983、rs63749993、rs671、rs7206735 And rs7447927.
Above-mentioned a kind of for detection be esophageal cancer susceptibility kit, wherein, described kit also include Taq enzyme, DNTP mixed liquor, MgCl2Solution, PCR reaction buffer, endonuclease reaction buffer solution, deionized water.
Kit of the present invention is the cancer of the esophagus crowd with the present inventor based on multiple international and national large sample amounts Based on the early-stage Study of normal population oesophagus cancer susceptibility gene screening results, by the cancer of the esophagus of the present inventor's autonomous Design SNP screening process, screens qualified SNP site from NCBI-pubmed database:1) search the literary composition related to the cancer of the esophagus Offer, by factor of influence with deliver the time limit and filtered;2) check the summary of candidate's document, further exclusion and cancer of the esophagus SNP Study unrelated document;3) read document, find the corresponding SNP site of the cancer of the esophagus;4) with the SNP site and the cancer of the esophagus chosen it is Keyword consulting literatures again;5) judge whether the SNP site chosen is closely related with the cancer of the esophagus, choose the closeest with the cancer of the esophagus SNP site, corresponding OR value and mutating alkali yl that cut is closed;6) SNP site that previous step is obtained, public by Sequenom Department software Typer 4.0 carries out online evaluation, obtains 24 final SNP site lists.
Compared with prior art, the invention provides a kind of detection method for detecting esophageal cancer susceptibility and reagent Box, has also reached following effect:24 SNP site of the present invention, through mcta analysis, have higher practicality, can be used for eating The earlier evaluations of pipe cancer and extensive examination, and this 24 sites detection success rate is high, technique reproducible is good, cost performance is high, For the risk assessment of the cancer of the esophagus, diagnosis with reference to providing important evidence, to realize the earlier evaluations to cancer of the esophagus disease.
Below just in conjunction with the embodiments, the specific embodiment of the present invention is described in further detail, so that technical scheme is more Should be readily appreciated that, grasp.
Specific embodiment
Below by specific embodiment, the present invention will be described, but the invention is not limited in this.In following embodiments Described experimental technique, if no special instructions, is conventional method;Described reagent and material, if no special instructions, all can be from business Approach obtains, and example below simultaneously is not used to limit the scope of the claims of the present invention, all equivalence enforcements done without departing from the present invention Or change, it is intended to be limited solely by this patent protection domain.
Embodiment 1 is used for detecting the SNP site that esophageal cancer susceptibility is related
Wherein, rs10204525 and rs1033667 is located at gene HEATR3 region, rs1042026 and rs1042522 is located at Gene C HEK2 region, rs10484761 is located at gene ST6GAL1 region, and rs11066015 is located at gene SMG6 region, Rs11066280 is located at gene PTPN2 region, and rs1346044 is located at Gene A DH1B region, and rs1642764 is located at Gene A LDH2 Region, rs17761864 is located at gene TMEM173 region, and rs1805034 is located at Gene A TP1B2 region, and rs1883965 is located at Gene HLA region, rs2074356 is located at gene PLCE1 region, and rs2239612 is located at gene M SH2 region, rs2274223 position In gene WRN region, rs238406 is located at gene ERCC2 region, and rs2847281 is located at gene PD-1 region, rs35597309 Positioned at Gene A LDH2 region, rs4785204 is located at gene TP53 region, and rs4822983 is located at gene RANK region, Rs63749993 is located at gene mTOR region, and rs671 is located at gene UNC5CL region, and rs7206735 is located at gene RPL6- PTPN11 region, rs7447927 is located at gene C 12orf51 region.
Embodiment 2 detects the kit of esophageal cancer susceptibility
First, the preparation of kit:
1st, design and the pcr amplification primer thing and the Single base extension primer that synthesize described 24 SNP site.SNP site to be measured Pcr amplification primer thing and Single base extension primer refer to table 1
The pcr amplification primer thing of table 1 SNP site to be measured and Single base extension primer
2nd, kit also includes Taq enzyme, dNTP mixed liquor, MgCl2Solution, PCR reaction buffer, endonuclease reaction buffering Liquid, deionized water.
2nd, the detection method of kit:
1st, the extraction of DNA
1.1 buccal swab DNA are extracted
1) buccal swab is placed in 2ml centrifuge tube, adds 400 μ l PBS.
2) 20 μ l QIAGEN Protease and 400 μ lBuffer AL are added.Vortex 15s mixes immediately.In order to ensure have The cracking of effect, sample and Buffer AL must immediately and be sufficiently mixed.
3) 56 DEG C of incubation 10min.Of short duration centrifugation.
4) add 400 μ l ethanol (96-100%) in sample, be vortexed and mix.Of short duration centrifugation is so that no liquid in lid.
5) liquid is transferred to centrifugal column, 8000rpm (6000 × g) is centrifuged 1min.
6) new 2ml EP pipe put into by pillar, plus 500 μ l Buffer AW1, and 8000rpm is centrifuged 1min, abandons EP pipe and gives up Liquid.
7) new 2mlEP pipe put into by pillar, plus 500 μ l Buffer AW2, and 14000rpm (20,000 × g) is centrifuged 3min, Abandon EP pipe and waste liquid.
8) pillar is put into new 2mlEP pipe, 14000rpm blank pipe is centrifuged 1min, abandons EP pipe.
9) pillar is put into new 1.5mlEP pipe, plus 120 μ l Buffer AE, incubated at room 5min, 8000rpm is centrifuged 1min, -20 DEG C of preservations.
1.2 whole blood DNAs extract
1) 20 μ l QIAGEN Protease are added in 1.5ml EP pipe.
2) to Guan Zhongjia 200 μ l whole blood sample.Note:The purpose being initially charged enzyme is to ensure that the mixing of enzyme and blood.
3) add 200 μ l Buffer AL, be vortexed and mix 15s.
4) 56 DEG C of incubation 10min, of short duration centrifugation.Note:Extending incubation time can not increase yield or improve quality.
5) 200 μ l absolute ethyl alcohols are added, after vortex 15s, of short duration centrifugation is so that no liquid in lid.
6) continue buccal swab 5~10 step.
2nd, PCR amplification
2.1 prepare pcr amplification reaction system in a new 1.5mlEP pipe, are shown in Table 2
Table 2 pcr amplification reaction system
Above reagent adds 2 μ l in every hole after mixing.
2.2 every holes sequentially add DNA 10ng/ul 1 μ l, 0.25uM Primer Mix 2 μ l, cumulative volume 5 μ l.
2.3 set in the PCR instrument of compatible 96 orifice plates PCR reaction condition as:94 DEG C of 4min, 94 DEG C of 20s, 56 DEG C 30min, 72 DEG C of 1min, 45 circulations;72℃3min;4 DEG C of holdings.96 hole PCR reaction plates are positioned in PCR instrument, start PCR Reaction.
3rd, PCR primer alkaline phosphatase treatment
3.1 after PCR reaction terminates, by PCR primer SAP (shrimp alkaline phosphatase, shrimp alkalescence Phosphatase) process, with remove system middle reaches from dNTPs.
3.2 preparation alkaline phosphatase treatment reaction systems, are shown in Table 3
Table 3 alkaline phosphatase treatment reaction system
Above reagent adds 2 μ l in every hole after mixing.
3.3 in the PCR instrument of compatible 96 orifice plates, sets PCR reaction condition:37℃40min;85℃5min;4 DEG C of holdings, Start PCR instrument and carry out alkaline phosphatase treatment.
4 Single base extensions
4.1 after alkaline phosphatase treatment terminates, and carries out single base extension.
4.2 preparation single base extension systems, are shown in Table 4
Table 4 single base extension system
Above reagent adds 1.06 μ l in every hole after mixing
4.3 every holes add iPLEX Extend Primer Mix 0.94 μ l, cumulative volume 9 μ l.
4.4 in the PCR instrument of compatible 96 orifice plates, sets PCR reaction condition:94 DEG C of 30s, 94 DEG C of 5s, 52 DEG C of 5s, 80 DEG C 5s;4 circulations of 52 DEG C of 5s, 80 DEG C of 5s;94 DEG C of 5s, 52 DEG C of 5s, 39 circulations of 80 DEG C of 5s;72℃3min;4 DEG C of maintenances.Start PCR instrument carries out single base extension.
5th, purifying resin
5.1 Clean Resin resin is tiled to 6mg resin plate in;
5.2 add 16 μ l water to the corresponding in the hole of extension products;
Dried resin is poured in extension products plate by 5.3, sealer, and slow speed vertical rotates 15min, make resin with anti- Thing is answered to be fully contacted;
5.4 3000rpm 5min centrifugations make resin sink to bottom hole portion.
6th, chip point sample
Start MassARRAY NanodispenserRS1000 point sample instrument, the extension products after purifying resin are moved to 96 On the solid support of hole, produce chip.
7th, Mass Spectrometer Method
Chip is used MALDI-TOF (matrix-assistedlaser desorption/ionization-time Offlight), matrix solid-dispersion flight time mass spectrum) analysis, testing result is using TYPER4.0 software (Sequenom) parting output result, analyzes experimenter's cancer of the esophagus occurrence risk, to realize the earlier evaluations to disease.
Embodiment 3 24 documents that SNP site quote closely related with the cancer of the esophagus, are shown in Table 5
Table 5 24 documents that SNP site quote closely related with the cancer of the esophagus
Embodiment 4 draws associating of 24 SNP site and the cancer of the esophagus according to the document quoted in embodiment 3, is shown in Table 6
6 24 SNP site of table and the association analysis result of the cancer of the esophagus
The checking of 5 24 SNP site of embodiment
Mass Spectrometry detection method using kit in above-described embodiment 2 analyzes 24 SNP site, and testing result uses 24 SNP site of table 6 and oesophagus in TYPER4.0 software (Sequenom) parting output result, its OR value and embodiment 4 The association analysis result of cancer is identical, illustrates that this 24 sites have higher practicality, can be used for the cancer of the esophagus earlier evaluations and Extensive examination, because analytical technique of mass spectrum has, detection success rate is high, technique reproducible is good, cost performance is high, the therefore present invention Use Mass Spectrometer Method to analyze this 24 sites detection success rate is high, technique reproducible is good, cost performance is high, is the trouble of the cancer of the esophagus Sick risk assessment, diagnosis reference provide important evidence, to realize the earlier evaluations to cancer of the esophagus disease.
Described above illustrate and describes some preferred embodiments of the present invention, but as previously mentioned it should be understood that the present invention Be not limited to form disclosed herein, be not to be taken as the exclusion to other embodiment, and can be used for various other combinations, Modification and environment, and can be in invention contemplated scope described herein, by technology or the knowledge of above-mentioned teaching or association area It is modified.And the change that those skilled in the art are carried out and change without departing from the spirit and scope of the present invention, then all should be at this In the protection domain of bright claims.
SEQUENCE LISTING
<110>Nucleon Gene Tech. Company Limited of Shenzhen
<120>A kind of kit for detecting esophageal cancer susceptibility and its SNP mark
<130>
<160> 72
<170> PatentIn version 3.5
<210> 1
<211> 29
<212> DNA
<213>Artificial sequence
<400> 1
acgttggatg tgttgggagg gcagaagtg 29
<210> 2
<211> 30
<212> DNA
<213>Artificial sequence
<400> 2
acgttggatg caggaatgag ttccaaggag 30
<210> 3
<211> 16
<212> DNA
<213>Artificial sequence
<400> 3
acctagggcc ccccat 16
<210> 4
<211> 31
<212> DNA
<213>Artificial sequence
<400> 4
acgttggatg gcttgttcat gcatgatgtt c 31
<210> 5
<211> 30
<212> DNA
<213>Artificial sequence
<400> 5
acgttggatg gttgtattac caggtggaag 30
<210> 6
<211> 16
<212> DNA
<213>Artificial sequence
<400> 6
gtgccaaaaa cctgga 16
<210> 7
<211> 30
<212> DNA
<213>Artificial sequence
<400> 7
acgttggatg gggcatttta tttgagttcc 30
<210> 8
<211> 30
<212> DNA
<213>Artificial sequence
<400> 8
acgttggatg gggtaaggta aaggatagac 30
<210> 9
<211> 22
<212> DNA
<213>Artificial sequence
<400> 9
aatttcctgt atttagaact ct 22
<210> 10
<211> 30
<212> DNA
<213>Artificial sequence
<400> 10
acgttggatg agttcccaga attccagagg 30
<210> 11
<211> 30
<212> DNA
<213>Artificial sequence
<400> 11
acgttggatg aagggacaga agatgacagg 30
<210> 12
<211> 14
<212> DNA
<213>Artificial sequence
<400> 12
agaggctgct cccc 14
<210> 13
<211> 30
<212> DNA
<213>Artificial sequence
<400> 13
acgttggatg agttcccaga attccagagg 30
<210> 14
<211> 30
<212> DNA
<213>Artificial sequence
<400> 14
acgttggatg ttggaaaggg tcccttcttc 30
<210> 15
<211> 18
<212> DNA
<213>Artificial sequence
<400> 15
gattaagagg cctgatgt 18
<210> 16
<211> 30
<212> DNA
<213>Artificial sequence
<400> 16
acgttggatg agttcccaga attccagagg 30
<210> 17
<211> 30
<212> DNA
<213>Artificial sequence
<400> 17
acgttggatg ttggttgtca cactctgtgg 30
<210> 18
<211> 14
<212> DNA
<213>Artificial sequence
<400> 18
gcctcaaccc actc 14
<210> 19
<211> 30
<212> DNA
<213>Artificial sequence
<400> 19
acgttggatg agttcccaga attccagagg 30
<210> 20
<211> 30
<212> DNA
<213>Artificial sequence
<400> 20
acgttggatg cagagaggtt ctttcctttg 30
<210> 21
<211> 19
<212> DNA
<213>Artificial sequence
<400> 21
tcagctattt ccacagaag 19
<210> 22
<211> 30
<212> DNA
<213>Artificial sequence
<400> 22
acgttggatg agttcccaga attccagagg 30
<210> 23
<211> 30
<212> DNA
<213>Artificial sequence
<400> 23
acgttggatg cgggaagaca tctccttttg 30
<210> 24
<211> 17
<212> DNA
<213>Artificial sequence
<400> 24
gcgaacttca accttca 17
<210> 25
<211> 30
<212> DNA
<213>Artificial sequence
<400> 25
acgttggatg agttcccaga attccagagg 30
<210> 26
<211> 30
<212> DNA
<213>Artificial sequence
<400> 26
acgttggatg tagtcccaac tactagggag 30
<210> 27
<211> 19
<212> DNA
<213>Artificial sequence
<400> 27
tggaattaag ctatcctcc 19
<210> 28
<211> 30
<212> DNA
<213>Artificial sequence
<400> 28
acgttggatg agttcccaga attccagagg 30
<210> 29
<211> 30
<212> DNA
<213>Artificial sequence
<400> 29
acgttggatg tcaccttgtc taaggaaacc 30
<210> 30
<211> 22
<212> DNA
<213>Artificial sequence
<400> 30
cgcaaaacaa ttatagatca ga 22
<210> 31
<211> 30
<212> DNA
<213>Artificial sequence
<400> 31
acgttggatg agttcccaga attccagagg 30
<210> 32
<211> 30
<212> DNA
<213>Artificial sequence
<400> 32
acgttggatg tggttttcta gctggcagag 30
<210> 33
<211> 18
<212> DNA
<213>Artificial sequence
<400> 33
ggacagagaa atccgaca 18
<210> 34
<211> 30
<212> DNA
<213>Artificial sequence
<400> 34
acgttggatg agttcccaga attccagagg 30
<210> 35
<211> 30
<212> DNA
<213>Artificial sequence
<400> 35
acgttggatg taaccaagct cagtttcggg 30
<210> 36
<211> 14
<212> DNA
<213>Artificial sequence
<400> 36
gccccaggga acac 14
<210> 37
<211> 30
<212> DNA
<213>Artificial sequence
<400> 37
acgttggatg agttcccaga attccagagg 30
<210> 38
<211> 30
<212> DNA
<213>Artificial sequence
<400> 38
acgttggatg agtccacaca gctggtaaac 30
<210> 39
<211> 17
<212> DNA
<213>Artificial sequence
<400> 39
tggtggttaa cagttca 17
<210> 40
<211> 30
<212> DNA
<213>Artificial sequence
<400> 40
acgttggatg agttcccaga attccagagg 30
<210> 41
<211> 30
<212> DNA
<213>Artificial sequence
<400> 41
acgttggatg gttcagcagc tcatgactcc 30
<210> 42
<211> 21
<212> DNA
<213>Artificial sequence
<400> 42
gtcataaata gaaactccag a 21
<210> 43
<211> 30
<212> DNA
<213>Artificial sequence
<400> 43
acgttggatg agttcccaga attccagagg 30
<210> 44
<211> 30
<212> DNA
<213>Artificial sequence
<400> 44
acgttggatg tccatcgaaa caccctgaac 30
<210> 45
<211> 19
<212> DNA
<213>Artificial sequence
<400> 45
aagatcttcg aagtgaatg 19
<210> 46
<211> 30
<212> DNA
<213>Artificial sequence
<400> 46
acgttggatg agttcccaga attccagagg 30
<210> 47
<211> 30
<212> DNA
<213>Artificial sequence
<400> 47
acgttggatg agtaccagta tgacaccagc 30
<210> 48
<211> 17
<212> DNA
<213>Artificial sequence
<400> 48
ccagtaacct cacagaa 17
<210> 49
<211> 30
<212> DNA
<213>Artificial sequence
<400> 49
acgttggatg agttcccaga attccagagg 30
<210> 50
<211> 30
<212> DNA
<213>Artificial sequence
<400> 50
acgttggatg ctctctgctg agaatgcaag 30
<210> 51
<211> 18
<212> DNA
<213>Artificial sequence
<400> 51
aggcagatca aactcacc 18
<210> 52
<211> 30
<212> DNA
<213>Artificial sequence
<400> 52
acgttggatg agttcccaga attccagagg 30
<210> 53
<211> 30
<212> DNA
<213>Artificial sequence
<400> 53
acgttggatg ccacattaag aagccctcag 30
<210> 54
<211> 14
<212> DNA
<213>Artificial sequence
<400> 54
tgctggccct gcat 14
<210> 55
<211> 30
<212> DNA
<213>Artificial sequence
<400> 55
acgttggatg agttcccaga attccagagg 30
<210> 56
<211> 30
<212> DNA
<213>Artificial sequence
<400> 56
acgttggatg aacctatgag gtaggtgaac 30
<210> 57
<211> 17
<212> DNA
<213>Artificial sequence
<400> 57
cctcactttc ccatttg 17
<210> 58
<211> 30
<212> DNA
<213>Artificial sequence
<400> 58
acgttggatg agttcccaga attccagagg 30
<210> 59
<211> 30
<212> DNA
<213>Artificial sequence
<400> 59
acgttggatg gcgcaacccc aactctaaaa 30
<210> 60
<211> 20
<212> DNA
<213>Artificial sequence
<400> 60
cagcaccatg cacaactaat 20
<210> 61
<211> 30
<212> DNA
<213>Artificial sequence
<400> 61
acgttggatg agttcccaga attccagagg 30
<210> 62
<211> 30
<212> DNA
<213>Artificial sequence
<400> 62
acgttggatg cgcctacttg gtctaagttg 30
<210> 63
<211> 19
<212> DNA
<213>Artificial sequence
<400> 63
actagggtga tagaactca 19
<210> 64
<211> 30
<212> DNA
<213>Artificial sequence
<400> 64
acgttggatg agttcccaga attccagagg 30
<210> 65
<211> 30
<212> DNA
<213>Artificial sequence
<400> 65
acgttggatg tggtggctac aagatgtcag 30
<210> 66
<211> 18
<212> DNA
<213>Artificial sequence
<400> 66
cactcacagt tttcactt 18
<210> 67
<211> 30
<212> DNA
<213>Artificial sequence
<400> 67
acgttggatg agttcccaga attccagagg 30
<210> 68
<211> 30
<212> DNA
<213>Artificial sequence
<400> 68
acgttggatg ccacattctc ttcctcaagc 30
<210> 69
<211> 18
<212> DNA
<213>Artificial sequence
<400> 69
aagaggcact aaagccta 18
<210> 70
<211> 30
<212> DNA
<213>Artificial sequence
<400> 70
acgttggatg agttcccaga attccagagg 30
<210> 71
<211> 30
<212> DNA
<213>Artificial sequence
<400> 71
acgttggatg taggagagcc accagagcac 30
<210> 72
<211> 15
<212> DNA
<213>Artificial sequence
<400> 72
ggaggctagg tggag 15

Claims (4)

1. a kind of SNP mark for detecting esophageal cancer susceptibility is it is characterised in that described SNP mark includes 24 SNP Site, described 24 SNP site be rs10204525, rs1033667, rs1042026, rs1042522, rs10484761, rs11066015、rs11066280、rs1346044、rs1642764、rs17761864、rs1805034、rs1883965、 rs2074356、rs2239612、rs2274223、rs238406、rs2847281、rs35597309、rs4785204、 Rs4822983, rs63749993, rs671, rs7206735 and rs7447927.
2. the pcr amplification primer thing of SNP mark according to claim 1 and Single base extension primer it is characterised in that
The sequence of the pcr amplification primer thing of described detection rs10204525 is respectively SEQ ID NO:1 and SEQ ID NO:2, and The sequence of Single base extension primer is SEQ ID NO:3;
The sequence of the pcr amplification primer thing of described detection rs1033667 is respectively SEQ ID NO:4 and SEQ ID NO:5, Yi Jidan The sequence of base extension primer is SEQ ID NO:6;
The sequence of the pcr amplification primer thing of described detection rs1042026 is respectively SEQ ID NO:7 and SEQ ID NO:8, Yi Jidan The sequence of base extension primer is SEQ ID NO:9;
The sequence of the pcr amplification primer thing of described detection rs1042522 is respectively SEQ ID NO:10 and SEQ ID NO:11, and The sequence of Single base extension primer is SEQ ID NO:12;
The sequence of the pcr amplification primer thing of described detection rs10484761 is respectively SEQ ID NO:13 and SEQ ID NO:14, with And the sequence of Single base extension primer is SEQ ID NO:15;
The sequence of the pcr amplification primer thing of described detection rs11066015 is respectively SEQ ID NO:16 and SEQ ID NO:17, with And the sequence of Single base extension primer is SEQ ID NO:18;
The sequence of the pcr amplification primer thing of described detection rs11066280 is respectively SEQ ID NO:19 and SEQ ID NO:20, with And the sequence of Single base extension primer is SEQ ID NO:21;
The sequence of the pcr amplification primer thing of described detection rs1346044 is respectively SEQ ID NO:22 and SEQ ID NO:23, and The sequence of Single base extension primer is SEQ ID NO:24;
The sequence of the pcr amplification primer thing of described detection rs1642764 is respectively SEQ ID NO:25 and SEQ ID NO:26, and The sequence of Single base extension primer is SEQ ID NO:27;
The sequence of the pcr amplification primer thing of described detection rs17761864 is respectively SEQ ID NO:28 and SEQ ID NO:29, with And the sequence of Single base extension primer is SEQ ID NO:30;
The sequence of the pcr amplification primer thing of described detection rs1805034 is respectively SEQ ID NO:31 and SEQ ID NO:32, and The sequence of Single base extension primer is SEQ ID NO:33;
The sequence of the pcr amplification primer thing of described detection rs1883965 is respectively SEQ ID NO:34 and SEQ ID NO:35, and The sequence of Single base extension primer is SEQ ID NO:36;
The sequence of the pcr amplification primer thing of described detection rs2074356 is respectively SEQ ID NO:37 and SEQ ID NO:38, and The sequence of Single base extension primer is SEQ ID NO:39;
The sequence of the pcr amplification primer thing of described detection rs2239612 is respectively SEQ ID NO:40 and SEQ ID NO:41, and The sequence of Single base extension primer is SEQ ID NO:42;
The sequence of the pcr amplification primer thing of described detection rs2274223 is respectively SEQ ID NO:43 and SEQ ID NO:44, and The sequence of Single base extension primer is SEQ ID NO:45;
The sequence of the pcr amplification primer thing of described detection rs238406 is respectively SEQ ID NO:46 and SEQ ID NO:47, and The sequence of Single base extension primer is SEQ ID NO:48;
The sequence of the pcr amplification primer thing of described detection rs2847281 is respectively SEQ ID NO:49 and SEQ ID NO:50, and The sequence of Single base extension primer is SEQ ID NO:51;
The sequence of the pcr amplification primer thing of described detection rs35597309 is respectively SEQ ID NO:52 and SEQ ID NO:53, with And the sequence of Single base extension primer is SEQ ID NO:54;
The sequence of the pcr amplification primer thing of described detection rs4785204 is respectively SEQ ID NO:55 and SEQ ID NO:56, and The sequence of Single base extension primer is SEQ ID NO:57;
The sequence of the pcr amplification primer thing of described detection rs4822983 is respectively SEQ ID NO:58 and SEQ ID NO:59, and The sequence of Single base extension primer is SEQ ID NO:60;
The sequence of the pcr amplification primer thing of described detection rs63749993 is respectively SEQ ID NO:61 and SEQ ID NO:62, with And the sequence of Single base extension primer is SEQ ID NO:63;
The sequence of the pcr amplification primer thing of described detection rs671 is respectively SEQ ID NO:64 and SEQ ID NO:65, and single alkali The sequence of base extension primer is SEQ ID NO:66;
The sequence of the pcr amplification primer thing of described detection rs7206735 is respectively SEQ ID NO:67 and SEQ ID NO:68, and The sequence of Single base extension primer is SEQ ID NO:69;
The sequence of the pcr amplification primer thing of described detection rs7447927 is respectively SEQ ID NO:70 and SEQ ID NO:71, and The sequence of Single base extension primer is SEQ ID NO:72.
3. a kind of kit for detecting esophageal cancer susceptibility is it is characterised in that described kit is included described in claim 2 The pcr amplification primer thing of SNP mark and Single base extension primer, for detecting that in peripheral blood DNA, 24 SNP site are rs10204525、rs1033667、rs1042026、rs1042522、rs10484761、rs11066015、rs11066280、 rs1346044、rs1642764、rs17761864、rs1805034、rs1883965、rs2074356、rs2239612、 rs2274223、rs238406、rs2847281、rs35597309、rs4785204、rs4822983、rs63749993、rs671、 Rs7206735 and rs7447927.
4. according to claim 3 a kind of be the kit of esophageal cancer susceptibility it is characterised in that described examination for detection Agent box also includes Taq enzyme, dNTP mixed liquor, MgCl2Solution, PCR reaction buffer, endonuclease reaction buffer solution, deionized water.
CN201611049684.XA 2016-11-24 2016-11-24 Kit for detecting esophagus cancer susceptivity and SNP (single nucleotide polymorphism) marker of kit Pending CN106434980A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611049684.XA CN106434980A (en) 2016-11-24 2016-11-24 Kit for detecting esophagus cancer susceptivity and SNP (single nucleotide polymorphism) marker of kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611049684.XA CN106434980A (en) 2016-11-24 2016-11-24 Kit for detecting esophagus cancer susceptivity and SNP (single nucleotide polymorphism) marker of kit

Publications (1)

Publication Number Publication Date
CN106434980A true CN106434980A (en) 2017-02-22

Family

ID=58218303

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611049684.XA Pending CN106434980A (en) 2016-11-24 2016-11-24 Kit for detecting esophagus cancer susceptivity and SNP (single nucleotide polymorphism) marker of kit

Country Status (1)

Country Link
CN (1) CN106434980A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110343765A (en) * 2019-08-09 2019-10-18 郑州大学第一附属医院 A kind of SNP marker and kit for cardia cancer people at highest risk's screening

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101608218A (en) * 2008-06-20 2009-12-23 上海主健生物工程有限公司 Esophageal cancer genetic test kit
CN103898197A (en) * 2012-12-25 2014-07-02 泰州医药城博奥邦科生物科技有限公司 Common malignant tumor susceptibility gene detection chip
CN104593499A (en) * 2015-01-20 2015-05-06 汕头大学医学院 Detection kit for carrying out efficient molecular subtyping on esophageal cancer susceptible gene loci

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101608218A (en) * 2008-06-20 2009-12-23 上海主健生物工程有限公司 Esophageal cancer genetic test kit
CN103898197A (en) * 2012-12-25 2014-07-02 泰州医药城博奥邦科生物科技有限公司 Common malignant tumor susceptibility gene detection chip
CN104593499A (en) * 2015-01-20 2015-05-06 汕头大学医学院 Detection kit for carrying out efficient molecular subtyping on esophageal cancer susceptible gene loci

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110343765A (en) * 2019-08-09 2019-10-18 郑州大学第一附属医院 A kind of SNP marker and kit for cardia cancer people at highest risk's screening

Similar Documents

Publication Publication Date Title
JP6760917B2 (en) Analysis of genomic fractions using polymorphic counts
CN106434979A (en) Kit for detecting gastric cancer susceptibility and SNP marker thereof
Jones et al. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms
US20190136330A1 (en) Method for screening cancer
CN104745710B (en) A kind of SNP mark related to primary hepatoma auxiliary diagnosis and its application
CN107208135A (en) Composition and method for carrying out DNA methylation assay measure
EP3034624A1 (en) Method for the prognosis of hepatocellular carcinoma
CN103384725A (en) Fetal genetic variation detection
CN106399561A (en) Prime, probe and kit for detecting polymorphism of CYP2C19 gene
CN107003314A (en) Composition and method for carrying out DNA methylation assay measure
CN106480212A (en) A kind of kit for detecting liver cancer susceptibility and its SNP mark
CN105567822B (en) A kind of genetic test primer sets and kit for cancer risk assessment
CN105969859A (en) Mammary-cancer-susceptible-gene detection chip and preparation method thereof
Lin et al. Novel identification of biofluids using a multiplex methylation sensitive restriction enzyme-PCR system
Schulpen et al. Dose response analysis of monophthalates in the murine embryonic stem cell test assessed by cardiomyocyte differentiation and gene expression
Gehrau et al. MicroRNA signature at the time of clinical HCV recurrence associates with aggressive fibrosis progression post-liver transplantation
CN106434978A (en) Kit for detecting susceptibility to lung cancer and SNP (Single Nucleotide Polymorphism) marker thereof
CN106755318A (en) A kind of kit and its SNP marks for detecting nasopharyngeal carcinoma neurological susceptibility
CN106434981A (en) Kit for detecting ovarian cancer susceptibility and SNP (single nucleotide polymorphism) marker thereof
CN106434980A (en) Kit for detecting esophagus cancer susceptivity and SNP (single nucleotide polymorphism) marker of kit
Zhang et al. Determination of ABO blood group genotypes using the real‑time loop‑mediated isothermal amplification method
CN106755323A (en) A kind of kit and its SNP marks for detecting cervical cancer susceptibility
Li et al. A method to evaluate genome-wide methylation in archival formalin-fixed, paraffin-embedded ovarian epithelial cells
CN106480211A (en) A kind of kit and its SNP mark for detection of testis cancer neurological susceptibility
Pernet et al. SARS-CoV-2 viral variants can rapidly be identified for clinical decision making and population surveillance using a high-throughput digital droplet PCR assay

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170222